Recent Updates
Recently added Catalysts
CBLL Positive Sentiment

Ceribell to Report Second Quarter 2025 Financial Results on August 5, 2025

Key Takeaway: Ceribell, Inc. has announced that it will release its financial results for the second quarter of 2025 on August 5, 2025. A conference call will follow the release, allowing management to discuss the results with investors. The company specializes in medical technology for neurological conditions and has developed an FDA-cleared EEG platform.
Price reaction · baseline $15.52 (2025-07-22 close) · hit after-hours · clean, no other CBLL news in the window
day 0 close · peak
+1.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Ceribell is actively engaging with investors through a scheduled conference call.
  • The company is focused on innovative technology for neurological conditions.
  • The Ceribell System is FDA cleared, indicating regulatory confidence in their product.

Full Press Release Details

SUNNYVALE, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the second quarter of 2025 after the close of trading on Tuesday, August 5, 2025. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on August 5, 2025.
Investors interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and providing access code 7468193. A live and archived webcast of the event will be available in the "Investor Relations" section of the Ceribell website athttps://investors.ceribell.com/.
About CeriBell, Inc.Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA 510(k) cleared for indicating suspected seizure activity and currently utilized in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visitwww.ceribell.comor follow the company onLinkedIn.

Investor ContactBrian Johnston or Laine MorganGilmartin GroupInvestors@ceribell.com

Media ContactCorrie RosePress@ceribell.com

Frequently Asked Questions

When will Ceribell report its Q2 2025 financial results?

Ceribell will report its Q2 2025 financial results on August 5, 2025.

How can investors join the Ceribell conference call?

Investors can join the conference call by dialing (800) 715-9871 for domestic calls.

What is the Ceribell System used for?

The Ceribell System is used for rapid diagnosis and monitoring of neurological conditions.

Is the Ceribell System FDA approved?

Yes, the Ceribell System is FDA 510(k) cleared for indicating suspected seizure activity.

Last updated: Jul 22, 2025